A review reaffirms that beremagene geperpavec, the first FDA-approved topical gene therapy, improves wound healing in dystrophic epidermolysis bullosa. The source notes durability depends on continued weekly dosing, keeping the treatment’s real-world regimen in focus as clinicians evaluate long-term outcomes and adherence.